A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

NCT02161185 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to slow enrollment. There were no safety concerns.

Conditions

Epilepsy

Interventions

DRUG: USL261

Sponsor

UCB Biopharma S.P.R.L.